Initial and final report on 3/5/2021, a customer called hologic technical support (ts) to report that they had three invalid aptima hpv assay runs.Product application specialists (pas) reviewed the logs from (b)(6) 2021, date the instrument was last serviced to (b)(6) 2021.Pas found that eight different hpv worklists were potentially impacted by an auto detect (ad) delay.In three of the eight worklists from (b)(6) 2021 and (b)(6) 2021, an ad delay was noted to potentially impact hpv results; overall a total of 36 potential false positive hpv results occurred.Customer was informed, but customer decided to only retest the affected worklist ran on (b)(6) 2021.The customer was notified that additional logs from before (b)(6) 2021.Could be reviewed, however, the customer decided to not have those worklists reviewed and did not upload the logs.Field service engineer went to the customer site and resolve the delay in injection problem.Per risk assessment, the severity associated with a false positive result using the aptima hpv assay is serious.To mitigate this risk, hologic requested the customer to retest the samples in question.If the patient received a false positive result for hpv, the potential impact to the patient would be inconvenience, anxiety, and over testing.If the false positive result was obtained during repeat co-testing, a colposcopy is recommended.
|